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Background:  Herpes  simplex  viruses  (HSV)  are  double-stranded  DNA  human  herpesviruses  (HHVs)  that
have the  capacity  to  cause  signiﬁcant  morbidity  and  mortality  in humans.  Like  HHV5  (Cytomegalovirus)
and  HHV8  (Kaposi’s  sarcoma  virus),  HSV  type  1 (HSV-1),  and  HSV  type  2  (HSV-2)  (HHV1,  HHV2)  selec-
tively  package  certain  viral  messenger  RNAs  inside  mature  virions,  as  well  as  expressing  those  mRNAs  in
infected cells.
Objectives: To  evaluate  the  clinical  and  analytical  performance  of  Aptima  HSV  1&2  assay  (AHSV),  a  newly
developed  automated  real time  transcription-mediated  ampliﬁcation  (TMA)  nucleic  acid ampliﬁcation
test  (NAAT)  for HSV-1  and  2 UL42  mRNAs,  compared  to  viral  culture  and  HSV  DNA  NAAT.
Study  design:  Cutaneous  and  mucocutaneous  lesion  swab  specimens  from  a population  of  symptomatic
female  and  male  subjects  attending  a U.S. public  health  clinic  (n  = 758)  were  evaluated  by  shell  vial  culture
with  ﬂuorescent  antibody  staining  for  HSV-1  and  2. Specimens  were  then  tested  with  AHSV for  HSV-1
and  2 on  the Panther  instrument.  Specimens  from  subjects  with  discordant  culture—TMA  paired  results
were  tested  using  an FDA-cleared  test  for HSV-1  and  2 viral  DNA.  Analytical  performance  of  AHSV  was
evaluated  using  test  panels  consisting  of laboratory  strains  of HSV-1  and  2  and a variety  of  non-target
human  DNA  viruses.
Results: Compared  to culture,  AHSV  was  sensitive  and  speciﬁc  for  detection  of  HSV-1  and  2  in patient
lesion  swab  specimens,  exhibiting  clinical  sensitivities  of  98.2%  (95%  CI: 92.9–99.7)  and 99.4%  (95%  CI:
96.0–99.9),  respectively.  Addition  of  HSV  DNA  NAAT  discordant  resolution  testing  results  to culture
results  improved  AHSV  sensitivity  for HSV-1  and  2–99.2%  (95%  CI: 94.7–99.9)  and  100%  (95%  CI:  97.5–100),
respectively.  Clinical  speciﬁcity  of  AHSV  for  HSV-1  and  2 detection  was  97.8%  (95%  CI: 96.3–98.8) and
94.5%  (95%  CI:  92.2–96.1),  respectively,  compared  to  culture;  and  99.5%  (95%  CI: 98.5–99.9) and  99.5%
(95%  CI: 98.3–99.7),  respectively,  compared  to  culture  with  discordant  resolution.  Analytical  sensitivity
(95%  limit  of detection)  of  AHSV  for HSV-1  (McIntyre  strain)  was 28.9  TCID50/mL  (95% FL:  23.4–37.9),
and 0.54  TCID50/mL  (95%  FL: 0.42–0.75)  for HSV-2  (MS  strain).  AHSV  did  not  cross-react  with laboratory
strains  of HHV-3,  HHV-4,  HHV-5,  HHV-6,  and  four  other  non-HHV  human  DNA  viruses.
Conclusions:  Real  time  transcription-mediated  ampliﬁcation  NAAT  for HSV  viral  mRNA  is a sensitive  and
speciﬁc  method  for detection  of herpes  simplex  virus  infection  in  symptomatic  patients.
utho© 2016  The  A This study evaluated the analytical and clinical performance of a novel molecular
est method for herpes simplex viruses.
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1. Background
The Herpesviridae family of enveloped double-stranded DNA
viruses are important human pathogens that have the capacity for
imposing signiﬁcant morbidity and mortality following infection,
and have been shown to increase risk for infection and transmis-
sion of other viruses, including human immunodeﬁciency virus and
human papillomavirus [1,2]. Herpes simplex virus type 1 (HSV-1)
and type 2 (HSV-2) are two of the eight known human herpes
e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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iruses (HHV), and are a common cause of oral and anogenital
esions. HSV-1 typically causes oral lesions and HSV-2 typically
auses genital lesions, although oral lesions due to HSV-2 occur
ccasionally, and genital lesions due to HSV-1 infection are increas-
ng [3,4].
For many years, cell culture was the gold standard method
or detection of HSV in lesion specimens. Nucleic acid ampliﬁca-
ion tests (NAATs) for detection of HSV genomic DNA have been
eveloped that are faster and more sensitive than culture [5–8].
owever, the early DNA-based NAATs were laboratory-developed
CR assays that are not practical for many clinical laboratories.
ore recently, FDA-cleared NAATs for HSV DNA detection have
ecome available which are more extensively validated and less
abor intensive than laboratory-developed PCR assays [9–12].
HSV-1 and 2 share a unique feature with HHV DNA viruses HHV-
 (Cytomegalovirus) and HHV-8 (Kaposi’s Sarcoma virus), in that
ertain viral mRNAs are selectively packaged inside the virion par-
icles as well as expressed inside infected cells [13–15]. This is
hought to provide these viruses with a pre-fabricated mRNA com-
lement that facilitates rapid expression of viral proteins soon after
iral entry into the host cell [13].
In this study, we evaluated a new approach for detecting HSV
nfection by use of a real-time transcription-mediated ampliﬁca-
ion NAAT for the qualitative detection and differentiation of viral
RNAs from HSV-1 and HSV-2.
. Objectives
This study evaluated the analytical and clinical performance of
he transcription mediated ampliﬁcation (TMA)-based Aptima HSV
&2 (AHSV) assay compared to HSV shell vial culture for detection
f HSV-1 and HSV-2 in cutaneous and mucocutaneous lesion spec-
mens obtained from symptomatic patients attending a U.S. public
ealth clinic.
. Study design
.1. Analytical specimen testing
For analytical sensitivity testing, laboratory strains of HSV-1
McIntyre Strain, ATCC VR-539, American Type Culture Collection,
anassas, USA) and HSV-2 (MS  strain, ATCC VR-540) were grown
n monolayer tissue culture and the viral titer (50% tissue culture
nfectious dose/mL [TCID50/mL]) determined by end point dilution.
SV-1 and HSV-2 viral stocks were then diluted into Aptima sam-
le transport medium (STM; Hologic, Inc, San Diego, USA) to yield
ight panels ranging from 30 TCID50/mL  to 0.003 TCID50/mL. For
ach virus-positive panel and a negative STM panel, 60 replicates
ere tested using combinations of two Panther instruments and
wo separate AHSV reagent lots. The analytical sensitivity of AHSV
or detecting HSV-1 and 2 nucleic acids was determined by synthe-
izing in vitro RNA transcripts from plasmid DNA vectors containing
SV-1 or 2 UL42 gene sequences, followed by serial dilution of RNAs
n Aptima STM to create eight RNA-positive test panels for each viral
ype.
Analytical speciﬁcity of AHSV was determined by performing
ross reactivity and interference testing with 46 closely related
iruses, common ﬂora and opportunistic organisms (34 bacteria, 10
iruses, 1 protozoa, 1 yeast) that may  be found in skin and anogen-
tal specimens. Organisms were combined into 12 different pools
ased on microorganism type and panels were prepared by spik-
ng into Aptima STM to create a bulk stock, with three aliquots
ade from each stock. One aliquot was left negative to assess cross-
eactivity, the second aliquot was spiked with HSV-1 UL42 RNA
t 100 copies per reaction to assess interference with detection ofcal Virology 80 (2016) 62–67 63
HSV-1 and the third aliquot was  spiked with HSV-2 UL42 RNA at 100
copies per reaction to assess interference with detection of HSV-2.
Ten replicates were tested from each panel member. Most organ-
isms were spiked at 1 × 106 colony forming units (CFU)/reaction
or cells/reaction. Two organisms were spiked below this concen-
tration due to limited available initial concentrations. No organism
was spiked at less than 4 × 104 CFU/reaction or cells/reaction. Puri-
ﬁed and quantiﬁed DNA or RNA (4 × 104 copies per reaction) was
used for ﬁve of the microorganisms because cultured material was
not available.
3.2. Clinical specimens
A total of 758 lesion swab specimens collected from patients
seen at Public Health-Seattle & King County clinics were included
in the study, of which 663 were genital, 72 were oral/facial, 16
were skin and 7 were not otherwise speciﬁed. Lesion swab spec-
imens were placed in Universal Transport Medium (UTM, Copan
Diagnostics, Murrieta, CA) and stored at 4 ◦C for 1–3 days before
testing by HSV shell vial culture. Specimens were stored at −70 ◦C
for 1–16 months and tested retrospectively by AHSV on the Panther
instrument.
3.3. Shell vial culture
Specimens were tested for HSV-1 and HSV-2 by MRC-5 shell
vial centrifugation culture using the MicroTrak HSV 1/HSV 2Culture
Identiﬁcation/Typing Test (Trinity Biotech, Jamestown, NY) [16].
Brieﬂy, 0.2 mL  of specimen was inoculated into two  MRC-5 shell
vials, the shell vials were centrifuged at 700g for 1 h and incubated
at 37 ◦C for 16–20 h, and the two shell vial coverslips were ﬁxed and
stained with ﬂuorescein-labeled monoclonal antibodies to either
HSV-1 or HSV-2.
3.4. HSV nucleic acid ampliﬁcation testing
Clinical specimens and panels of laboratory-derived viral strains
were tested with the Aptima HSV 1&2 assay (AHSV), a research use
only real time transcription mediated ampliﬁcation (TMA) assay
that detects and differentiates HSV-1 and HSV-2 UL42 mRNAs
expressed in infected cells and packaged in HSV-1 and HSV-2 viri-
ons (Fig. 1). For AHSV, 0.5 mL  of each UTM specimen was  added to
an Aptima Specimen Transport Tube containing 2.9 mL  of Aptima
STM, and 0.4 mL  of the diluted specimen was  processed by mag-
netic bead-based RNA target capture followed by real time TMA
for amplicon generation and detection on the Panther automated
instrument (Hologic, Inc, San Diego CA). A relative ﬂuorescence unit
range cutoff of greater than 1000 was used to determine sample
reactivity status. All AHSV testing was  performed on a blinded basis
at Hologic. Positive and negative run controls consisting of HSV-1
and 2 UL42 RNAs at 750 copies/mL each, or negative STM, respec-
tively, were included in every run on the Panther instrument and
were used to validate run performance.
3.5. Discrepant analysis
AHSV was compared to shell vial culture as the reference
standard to calculate sensitivity and speciﬁcity, before and after
discordant analysis using the AmpliVue HSV 1 + 2 Assay (Quidel,
Athens, OH), a FDA-cleared NAAT. The AmpliVue Assay is a heli-
case dependent ampliﬁcation assay that detects and differentiates
HSV-1 and HSV-2 genomic DNA. For the AmpliVue assay, 20 L of
UTM specimen was added to a Dilution Tube containing 1.6 mL  of
Dilution Buffer, 50 L of the diluted specimen was added to a Reac-
tion Tube, and the Reaction Tube was incubated for 45 min at 64
◦
C
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F ed from HSV genomes in infected cells, by real-time transcription-mediated ampliﬁcation.
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Table 1
Analytical sensitivity of Aptima HSV1&2 assay.
Sample Limit of Detection
95% 50%
HSV−1 McIntyre straina 28.9 (23.4–37.9) 9.9 (8.2–11.8)
HSV−2  MS straina 0.54 (0.42–0.75) 0.14 (0.11–0.18)
HSV1 UL42 RNAb 68.3 (51.8–100.1) 16.1 (12.5–20)
HSV2 UL42 RNAb 49.4 (37.2–75.2) 12.7 (9.9–15.7)ig. 1. Detection of HSV 1&2 UL42 mRNA packaged inside viral particles and express
C,  internal control signal.
nd inserted into a disposable lateral ﬂow device for detection of
mpliﬁed DNA.
.6. Statistical analysis
All tests for 95% conﬁdence intervals for proportions were
wo-tailed and performed at the 5% signiﬁcance level using the
fﬁcient-score method [17]. Probit analysis for estimating percent
eactivity levels with 95% ﬁduciary limits (FL) was performed using
he Gompertz model method using PC SAS version 9.3 or higher.
. Results
Table 1 shows the analytical sensitivity of AHSV determined
sing serial dilution panels of laboratory-grown HSV-1 and HSV-
 strains. From probit analysis of results from 540 replicates tested
or each viral type, the 95% and 50% limit of detection values in
CID50/mL for HSV-1 were 28.9 (95% FL: 23.4–37.9) and 9.9 (95% FL:
.2–11.8), respectively. Similarly, for HSV-2 the 95% and 50% limit
f detection values were 0.54 (95% FL: 0.42–0.75) and 0.14 (95%
L: 0.11–0.18) TCID50/mL, respectively. To determine the analyti-
al sensitivity of AHSV for detecting HSV UL42 mRNAs, in vitro RNAa Values are TCID50/mL  (95% Fiduciary Limit).
b Values are copies/mL (95% Fiduciary Limit).
transcripts corresponding to HSV-1 and HSV-2 UL42 mRNAs were
diluted serially in Aptima STM and tested in parallel with the viral
lysate panels. Probit analysis yielded 95% and 50% limit of detec-
tion values for HSV-1 RNA of 68.3 (95% FL: 51.8–100.1) and 16.1
(95% FL: 12.5–20) copies/mL, respectively. For HSV-2 RNA the 95%
and 50% limit of detection values were 49.4 (95% FL: 37.2–75.2) and
12.7 (95% FL: 9.9–15.7) copies/mL, respectively.The capacity of non-HSV DNA viruses to cross react or inter-
fere with AHSV was  evaluated by testing Aptima STM lysate panels
containing low titer HSV-1 and 2, and high titer (105 IU/mL) non-
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Table  2
Analytical speciﬁcity of Aptima HSV1&2 assay; cross reactivity and interference testing with non-HSV DNA viruses.
Panel Titer AHSV1&2 Assay Result by Test Sample Matrixa
HSV Neg HSV-1b HSV-2b
HSV-1 1 × 106 c 100 (HSV-1), 0 (HSV-2) – –
HSV-2  1 × 106 c 0 (HSV-1), 100 (HSV-2) – –
HSV-1:HSV-2 1 × 106:1 × 102 d 100 (HSV-1), 100 (HSV-2) – –
HSV-1:HSV-2 1 × 102:1 × 106 d 100 (HSV-1), 100 (HSV-2) – –
HHV-3 (Varicella zoster) 1 × 105 0 100 100
HHV-4 (Epstein Barr Virus) 1 × 105 0 100 100
HHV-5 (Cytomegalovirus) 1 × 105 0 100 100
HHV-6 (roseola) 1 × 105 0 100 100
Adenovirus Type 1 1 × 105 0 100 100
BK  Virus 1 × 105 0 100 100
Hepatitis B virus 1 × 105 0 100 100
Parvo  B19 1 × 105 0 100 100
a Values are % reactive; n = 10 replicates per determination.
b Titer = 3-fold above the 95% LOD.
c TCID50/mL  for HSV 1&2; IU/mL for all other viruses.
d Copies/reaction UL42 mRNA.
Table 3
Detection of HSV-1 and HSV-2 in infected patient specimens by Aptima HSV 1&2
assay.
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Table 4
Comparison of Aptima HSV1&2 assay and Shell Vial Culture for detection of HSV-1
and HSV-2.
Aptima HSV1&2 Shell Vial Culture
HSV-1 HSV-2
Positive Negative Total Positive Negative Total
HSV-1 Positive 107 14a 121
HSV-1 Negative 2b 635 637
Total 109 649 758
HSV-2 Positive 159 33c 192
HSV-2 Negative 1d 565 566
Total 160 598 758
a 11+, 3-, by FDA-cleared HSV assay.
b 1+, 1-, by FDA-cleared HSV assay.
c 29+, 3-, 1 not tested, by FDA-cleared HSV assay.
d 0+, 1-, by FDA-cleared HSV assay.
Table 5
Clinical sensitivity and speciﬁcity estimates for Aptima HSV1&2 assay.
Aptima HSV 1&2 Reference Standard
Culture Culture + Discordant Resolutiona
HSV-1 Sensitivity 98.2 (92.9–99.7) 99.2 (94.7–99.9)
Speciﬁcity 97.8 (96.3–98.8) 99.5 (98.5–99.9)
PPV 88.4 (81.0–93.3) 97.5 (92.4–99.4)
NPV 99.7 (98.7–99.9) 99.8 (98.9–99.9)
Overall Agreement 97.9 (96.6–98.7) 99.5 (98.7–99.8)
HSV-2 Sensitivity 99.4 (96.0–99.9) 100 (97.5–100)
Speciﬁcity 94.5 (92.2–96.1) 99.5 (98.3–99.7)
PPV 82.8 (76.6–87.7) 98.4 (95.1–99.6)
NPV 99.8 (98.9–99.9) 100 (99.2–100)
Overall Agreement 95.5 (93.8–96.8) 99.6 (98.8–99.9)arget DNA viruses (Table 2). None of these non-HSV DNA viruses
ere detected by AHSV, and there was no inhibition of detection
y AHSV of low-positive HSV-1 and HSV-2 samples by high titers of
hese non-target DNA viruses. AHSV also did not cross-react with
1 species of clinically relevant bacteria and yeast when tested at
igh titer (data shown in Supplementary table).
To assess the analytical sensitivity of AHSV for detecting HSV
RNA in specimens from naturally infected HSV-positive subjects,
0 HSV-1 and 10 HSV-2 positive swab specimens were diluted 1/50
o 1/100,000 with Aptima STM and tested using 3 replicates at each
ilution (Table 3). All 20 samples remained 3/3 positive at the 1/50
ilution level, 16 of 20 samples (8 HSV-1 and 8 HSV-2) were 3/3
ositive at the 1/500 dilution level, and 12 of 20 samples (5 HSV-1
nd 7 HSV-2) had partial positivity following 1/100,000 dilution.
To evaluate the clinical performance of AHSV, cutaneous and
ucocutaneous swab specimens in viral transport medium from
58 symptomatic patients were tested by both shell vial cell culture
nd AHSV. AHSV was HSV-1 positive for 107 of 109 (98.2%) HSV-
 culture positive specimens and HSV-1 negative for 635 of 649
97.8%) HSV-1 culture negative specimens, for an overall agreementValues are % (95% CI).
a FDA-cleared HSV1&2 assay.
of 97.9% for HSV-1 (Tables 4 and 5). For HSV-2, AHSV was positive
for 159 of 160 (99.4%) HSV-2 culture positive specimens and HSV-2
negative for 565 of 598 (94.5%) HSV-2 culture negative specimens,
for an overall agreement of 95.5% for HSV-2 (Tables 4 and 5). One
specimen was  AHSV positive for both HSV-1 and HSV-2 but only
HSV-2 positive by culture. Using culture as the reference standard,
there were 16 HSV-1 discordant results (14 false positive and 2 false
negative) and 34 HSV-2 discordant results (33 false positive and 1
false negative) by AHSV. (Table 4).
AmpliVue HSV 1 + 2 testing of the 16 HSV-1 discordants deter-
mined that 11 of 14 apparent HSV-1 false-positive AHSV results
were true positives, and 1 of 2 apparent HSV-1 false-negative AHSV
6 f Clini
r
p
A
c
f
e
O
a
d
9
d
a
a
t
a
(
s
r
r
5
b
H
F
(
M
1
1
O
C
i
T
m
s
c
c
s
s
t
a
R
H
p
a
T
f
p
H
b
d
l
N
h
t
u
f
v
s
t
i6 P.D. Swenson et al. / Journal o
esults was a true negative (Table 4). The specimen that was AHSV
ositive for both HSV-1 and HSV-2 was only HSV-2 positive by
mpliVue. AmpliVue testing of 33 of the 34 samples with dis-
ordant HSV-2 results determined that 29 of 32 apparent HSV-2
alse-positive AHSV results were true positives, while the 1 appar-
nt HSV-2 false-negative AHSV result was a true negative (Table 4).
ne of the alleged HSV-2 false-positive AHSV specimens was  not
vailable for AmpliVue testing.
The overall agreement between AHSV and culture with discor-
ant resolution by AmpliVue was 99.5% (754/758) for HSV-1 and
9.6% (754/757) for HSV-2 (Table 5). Using culture with discor-
ant resolution by AmpliVue as the reference standard, AHSV had
 sensitivity and speciﬁcity of 99.2% (95% CI: 94.7–99.9) (118/119)
nd 99.5% (95% CI: 98.5–99.9) (636/639), respectively, for detec-
ion of HSV-1; and 100% (95% CI: 97.5–100) (188/188) sensitivity
nd 99.5% (98.3–99.7) (566/569) speciﬁcity for detection of HSV-2
Table 5). After discordant resolution using AmpliVue, culture had a
ensitivity and speciﬁcity of 90.1% (108/119) and 99.8% (638/639),
espectively, for HSV-1 and 84.6% (159/188) and 99.8% (568/569),
espectively, for HSV-2 (analysis not shown).
. Discussion
Clinically validated NAATs targeting HSV genomic DNA are
ecoming increasingly available for detection and differentiation of
SV-1 and HSV-2 in lesion specimens. Several NAATs are currently
DA-cleared, including the BD ProbeTec Herpes Simplex Viruses
HSV 1 & 2), Qx Ampliﬁed DNA Assays (BD Diagnostics, Sparks,
D), AmpliVue HSV 1 + 2 Assay (Quidel, Athens, OH), cobas HSV
 and 2 Test (Roche Diagnostics, Indianapolis, IN), illumigene HSV
 & 2 DNA Ampliﬁcation Assay (Meridian Bioscience, Cincinnati,
H), and Simplexa HSV 1 & 2 Direct (Focus Diagnostics, Cypress,
A).
In this study, we evaluated the analytical performance and clin-
cal utility of the Aptima HSV 1&2 assay, an automated real time
MA  assay designed to detect HSV-1 and 2 viral mRNAs, namely
RNAs encoded by the UL42 gene of both virus types. The results
how that AHSV is very sensitive analytically, detecting less than 70
opies/mL of HSV-1 UL42 RNA (28 copies/reaction) and less than 50
opies/mL of HSV-2 UL42 RNA (20 copies/reaction), and clinically
ensitive compared to a culture-DNA NAAT composite reference
tandard. The UL42 gene encodes a DNA polymerase accessory pro-
ein that is essential for viral replication, and is highly conserved
mong HSV viral isolates and types [18]. Along with other viral
NAs, UL42 mRNAs are actively and selectively packaged inside
SV-1 and 2 virus particles by binding to speciﬁc viral tegument
roteins [19]. Packaging of multiple copies of mRNAs per virion [13]
llows for sensitive detection of intact virus and infected cells by
MA, as indicated by the low TCID50/mL  sensitivity values achieved
or AHSV using cultured virus isolates, as well as the reproducible
ositive detection results observed for AHSV in extensively diluted
SV-positive clinical samples.
For clinical performance evaluation, after discordant resolution
y AmpliVue AHSV was more sensitive than shell vial culture for the
etection of HSV-1 (99.2% vs 90.1%) and HSV-2 (100% vs 84.6%) in
esion swab specimens. Other studies comparing HSV DNA-based
AATs to cell culture with molecular test discordant resolution
ave also reported greater sensitivity of those NAATs over cul-
ure [5–12], especially for detection of HSV-2 [9,10]. These studies
sed several different culture methods to evaluate the clinical per-
ormance of NAATs, including conventional culture [6,10], shell
ial centrifugation culture [5,12], and ELVIS culture [7–9,11]. The
hell vial centrifugation method used in the current study is faster
han conventional culture and, unlike ELVIS, it can detect HSV-1
n HSV-2 positive specimens. Although AHSV detected more HSVcal Virology 80 (2016) 62–67
infections than shell vial culture, it still had good overall agreement
with cell culture for detection of HSV-1 and HSV-2 in lesion swab
specimens. Discordant analysis performed with the FDA-cleared
AmpliVue HSV test indicated that AHSV is highly accurate, with
resolved positive predictive values ≥97.5% and negative predictive
values ≥99.8% for detection and differentiation of HSV-1 and HSV-2.
The results from this study indicate that HSV mRNA detection by
NAAT offers a sensitive and speciﬁc method for diagnosis of patients
infected with HSV-1 and 2. This RNA-targeting approach may  prove
useful for developing diagnostic tests for other RNA-containing
DNA viruses.
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